Clinical Trials Logo

Primary Open Angle Glaucoma clinical trials

View clinical trials related to Primary Open Angle Glaucoma.

Filter by:

NCT ID: NCT04609345 Not yet recruiting - Ocular Hypertension Clinical Trials

Prevalence of Ocular Surface Disease in Malaysian Glaucoma Patients

Start date: November 2020
Phase:
Study type: Observational

This is a prospective, multi-centre, cross sectional observational study to determine the prevalence of ocular surface disease (OSD) in glaucoma patients, nationwide. The study also analyses sub group of OSD prevalence, stratified according to the treatment types (i.e. preserved, preservative-free, and combination of preservative-free and preserved eyedrops), and illustrates the patient perspective on OSD.

NCT ID: NCT04595227 Recruiting - Ocular Hypertension Clinical Trials

Glaucoma Screening Using Dynamic Analysis of Computerized Pupillary Light Reflex Assessment Device

Start date: October 30, 2020
Phase:
Study type: Observational

To explore an effective diagnostic tool of glaucoma through the dynamic analysis of computerized pupillary light reflex assessment device (CPLRAD) pupillography based on iris recognition techniques and investigate its feasibility in glaucoma screening.

NCT ID: NCT04553523 Recruiting - Clinical trials for Primary Open Angle Glaucoma

Hydrus® Microstent New Enrollment Post-Approval Study

CONFIRM
Start date: August 25, 2020
Phase: N/A
Study type: Interventional

The purpose of this post-approval study is to evaluate the rate of Hydrus Microstent malposition and associated clinical sequelae occurring within 24 months post-operation. Qualified subjects will undergo uncomplicated cataract surgery with placement of a monofocal intraocular lens (IOL), followed by implantation of the Hydrus Microstent.

NCT ID: NCT04519814 Active, not recruiting - Clinical trials for Primary Open-angle Glaucoma

Safety and Effectiveness of VISULAS Green Selective Laser Trabeculoplasty (SLT)

Start date: June 3, 2020
Phase: N/A
Study type: Interventional

An interventional, open, prospective, multi-center pre-market clinical investigation according to §§20-23a Medizinproduktegesetz (MPG, medical devices act), in which a total of 40 eyes of 40 consecutive patients at up to five (5) clinical sites will be enrolled, treated with the VISULAS green with option CSLT, and followed for a three months period. The primary objective of this clinical investigation is to evaluate safety and effectiveness of SLT with the VISULAS green laser with option CSLT.

NCT ID: NCT04461249 Completed - Clinical trials for Primary Open Angle Glaucoma

Comparison Between Latanoprost , Travoprost and Tafluprost in Reducing IOP Fluctuation in POAG Patients

Start date: June 1, 2019
Phase:
Study type: Observational

Elevated IOP is a key risk factor for the progression of glaucoma. IOP is subjected to diurnal fluctuation in healthy individuals and higher fluctuation in POAG . So, once-daily antiglaucoma drugs must have consistent efficacy throughout the day. Prostaglandin analogues (PGAs) have become the first-line drops for medical treatment of glaucoma worldwide. In our study, we compare between the efficacy and tolerability of Latanoprost 0.005%, Travoprost 0.004% and Tafluprost 0.0015% on diurnal IOP fluctuation in patients having POAG, IOP fluctuation was assessed before treatment , then 2 weeks and 6 weeks after. A comparable and significant reduction in IOP fluctuation occurred in the 3 groups. Side effects were mild and tolerable.

NCT ID: NCT04454190 Terminated - Glaucoma Clinical Trials

Development and Validation of a Model to Predict Fast Progression in Glaucoma

Start date: July 20, 2021
Phase:
Study type: Observational

1. The purpose of this study is to obtain genetic data on a well-defined population of patients with glaucoma that had accurate measurements of rates of structural and functional change over time. 2. The investigators aim to recruit 5,000 patients for Phase I and 100 patients for Phase II over a period of 2 years for obtaining blood samples which will be processed for extraction of DNA and genotyping. Phase II also includes eye examination. Patients will be selected from the Duke Glaucoma Registry (DGR) database and will be contacted by phone, mail or email using a standardized script and procedure. 3. Data analysis, based on patient-blind (no personal health information) data will take place at Duke and Genentech. No protected health information (PHI) will leave Duke. Standard statistical methods will be used to analyze the collected data and to develop predictive statistical models for fast progression in glaucoma. Risks from participating in the study are low and include loss of confidentiality and inherent issues related to drawing blood.

NCT ID: NCT04448223 Recruiting - Ocular Hypertension Clinical Trials

A Clinical Study to Evaluate the Efficacy and Safety of CKD-351

Start date: June 11, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate efficacy and safety of CKD-351

NCT ID: NCT04440527 Not yet recruiting - Clinical trials for Primary Open Angle Glaucoma

Intraocular Pressure After Preserflo / Innfocus Microshunt Implantation vs Trabeculectomy

PAINT
Start date: July 22, 2020
Phase: N/A
Study type: Interventional

The aim of this project is to compare trabeculectomy with Preserflo / Innfocus Microshunt in patients with Primary Angle Open Glaucoma and Pseudoexfoliation Glaucoma regarding the reduction of intraocular pressure.

NCT ID: NCT04430296 Not yet recruiting - Clinical trials for Primary Open Angle Glaucoma

Cyclophotocoagulation in Primary Open Angle Glaucoma

Start date: August 1, 2020
Phase: N/A
Study type: Interventional

The use of Cyclodestruction procedures has been extended to patients with non-refractory glaucoma and good vision. Our aim is to compare the safety and efficacy of three cyclodestructive treatments; High Intensity Focused Ultrasound (HIFU) Cyclocoagulation versus micropulse cyclophotocoagulation (MP-CPC) versus transscleral continuous wave cyclophotocoagulation (CW-CPC) for the treatment of Primary open angle glaucoma.

NCT ID: NCT04405245 Completed - Ocular Hypertension Clinical Trials

Study to Assess the Efficacy, Safety and Tolerability of AKB-9778 Ophthalmic Solution as and Adjunct to Latanoprost in Patients With Ocular Hypertension or Open Angle Glaucoma

Start date: June 6, 2020
Phase: Phase 2
Study type: Interventional

This is a phase 2, double masked, randomized, multi-center, parallel-group, 28-day study assessing the safety, tolerability and ocular hypotensive efficacy of AKB-9778 Ophthalmic Solution 4.0% administered once (AM) or twice (AM & PM) daily when used as an adjunctive therapy to latanoprost ophthalmic solution 0.005% once daily (PM) in subjects with elevated IOP due to OAG or OHT.